Embecta (EMBC) vs OraSure Technologies (OSUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OraSure Technologies (OSUR) has outperformed Embecta (EMBC) over the past year, gaining 17.1% versus a loss of 58.4%. Embecta is the larger company by market cap ($331.7 million vs $267.9 million), about 1.2 times the size. Embecta pays a dividend yielding 7.86%, while OraSure Technologies does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | OSUR |
|---|---|---|
| Share price | $5.86 | $3.89 |
| Market cap | $331.74M | $267.94M |
| 1-day change | +1.83% | +2.37% |
| YTD return | -51.60% | +56.82% |
| 1-year return | -58.39% | +17.13% |
| 5-year return | — | -63.89% |
| P/E ratio (TTM) | 3.98 | — |
| Forward P/E | 3.32 | — |
| EPS (TTM) | $1.47 | $-0.69 |
| Dividend yield | 7.86% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| 52-week high | $14.91 | $4.58 |
| 52-week low | $2.77 | $2.08 |
| Distance from 52-week high | -60.73% | -15.17% |
| Analyst consensus | none | none |
| Avg. price target upside | -31.68% | +2.96% |
| Average volume | 1.37M | 484.72K |
| Shares outstanding | 56.66M | 68.97M |
| Employees | 1,850 | 500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSUR has outperformed EMBC by 75.5 percentage points over the past year.
- Embecta offers a meaningfully higher dividend yield (7.86% vs 0.00%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About OraSure Technologies
OSUR stock →OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Health Care · Medical/Dental Instruments · 500 employees
EMBC vs OSUR FAQ
Which is bigger, Embecta or OraSure Technologies?
Embecta (EMBC) is larger, with a market capitalization of $331.74M compared with $267.94M for OraSure Technologies (OSUR).
Which stock has performed better over the past year, EMBC or OSUR?
OSUR returned +17.13% over the past 12 months, compared with -58.39% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Embecta or OraSure Technologies?
Embecta pays a dividend yielding 7.86%, while OraSure Technologies does not currently pay a regular dividend.
Are Embecta and OraSure Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.